Not a single study
Story checked
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial | Reuters (opens in a new tab)
reuters.com · 2026-09-30
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial | Reuters
reuters.com · 2026-09-30
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedRegeneron's experimental weight-loss drug trevogrumab, used with Novo Nordisk's semaglutide, reduced the loss of muscle mass by 50% compared with semaglutide alone in a study of patients with obesity.View evidenceHide evidence
As stated50%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedWhen researchers measured thigh muscle by MRI scans, the addition of a 75-milligram dose of trevogrumab preserved over 70% of muscle mass loss compared with semaglutide alone at 52 weeks.View evidenceHide evidence
As statedover 70%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedIn one part of the trial, patients on semaglutide alone lost 6.7% of their lean muscle mass over 26 weeks; those taking 75 mg of trevogrumab lost 3.3%, and those taking 25 mg lost 4.7%.View evidenceHide evidence
As stated6.7%, 3.3%, and 4.7%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedRegeneron said the 75-mg once-weekly dose was selected for further studies and that another mid-stage trial in patients over 65 is planned.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe trevogrumab/garetosmab combination produced greater lean-mass preservation than trevogrumab alone but had a high rate of adverse side effects, including muscle spasms, and Regeneron said it will not move forward with the triple combination.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Metabolism: Clinical and Experimental · 2024 · PubMed
1230-OR: Lean Mass Effects of Anti-GDF8 (Trevogrumab) ± Anti-Activin A (Garetosmab) in People Living with Obesity Treated with Semaglutide with or without Low Lean Mass at Baseline
Diabetes · 2026 · Crossref
Sarcopenia and Skeletal Muscle Dysfunction in Liver Cirrhosis: Clinical Perspectives of Myostatin Inhibition.
2026 · Europe PMC
Review for "Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study"
2025 · Crossref
Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies.
2026 · Europe PMC
And 10 more candidates considered.